RLY-2139
/ Relay Therap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 02, 2023
Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
(GlobeNewswire)
- "Paused near-term commercial readiness activities for CCA to align with the broader tumor agnostic opportunity being pursued....Announced plans to initiate RLY-2608 + fulvestrant + CDK4/6 triplet combinations in patients with PI3Kα-mutant, HR+, HER2- locally advanced or metastatic breast cancer by the end of 2023....Paused further development efforts on RLY-2139 (CDK2 inhibitor)....Anticipated Upcoming Milestones: (i) Lirafugratinib: report additional tumor agnostic clinical data and regulatory update in 2024; (ii) Pre-clinical: disclose new program(s) in 2024."
Clinical data • New trial • Pipeline update • Regulatory • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer
May 04, 2023
Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights
(GlobeNewswire)
- "Recent Corporate Highlights:...(i) RLY-5836 (pan-mutant and isoform-selective PI3Kα inhibitor): In April 2023, initiated a first-in-human trial in patients with advanced solid tumors with a PIK3CA (PI3Kα) mutation; (ii) RLY-2139 (CDK2 inhibitor): Selected development candidate; anticipate early 2024 clinical start, pending regulatory authorization."
New molecule • New trial • Trial status • Breast Cancer • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1